Aptabio Therapeutics Inc
293780
Company Profile
Business description
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.
Contact
13, Heungdeok 1-ro, Giheung-gu
Tower 504, Gyeonggi-do
Yongin-Si16954
KORT: +82 7071520097
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,961.70 | 8.20 | -0.10% |
| CAC 40 | 7,329.97 | 5.43 | -0.07% |
| DAX 40 | 21,311.02 | 57.32 | 0.27% |
| Dow JONES (US) | 39,669.39 | 699.57 | -1.73% |
| FTSE 100 | 8,275.60 | 26.48 | 0.32% |
| HKSE | 21,056.98 | 409.29 | -1.91% |
| NASDAQ | 16,307.16 | 516.01 | -3.07% |
| Nikkei 225 | 33,920.40 | 347.14 | -1.01% |
| NZX 50 Index | 12,032.77 | 35.15 | -0.29% |
| S&P 500 | 5,275.70 | 120.93 | -2.24% |
| S&P/ASX 200 | 7,758.90 | 2.80 | -0.04% |
| SSE Composite Index | 3,276.00 | 8.34 | 0.26% |